The burden of cervical cancer in the Central Asia and East Europe region is substantially higher than in the rest of Europe, with increasing trends of incidence and mortality in several countries. Approximately 40,000 women develop cervical cancer and 20,000 die from the disease yearly in this region. Consequently, in several Central Asia and East Europe countries, at least one woman in 50 will develop cervical cancer before the age of 75 year (1, 2, 3) .
An increasing number of valuable studies on gynecological cancer field have been presented in the literature over recent years in these regions. Based on the burden of cervical cancer in these regions and with the aim of conducting translational and clinical researches in all gynaecological fields, we planned to found a new research network.
Initially as a network of seven (Turkey, Russia, Iran, Kazakhstan, Armenia, Georgia, Azerbaijan) of “Central Asia and East Europe regional clinical trials groups”, the Central Asia and East Europe Trial Group (CENTEast) is a research network and was founded to provide active support to gynaecological researches and advancement in prevention, diagnostics and treatment of patients with gynecologic malignancies.